Table 3.

Effect of ER and p53 mutation on the association of Val16Ala with 10-year breast cancer survival

	Univariate		Multivariate*
	HR (95% CI)	P-value	HR (95% CI)	P-value
ER negative	(n=196)		(n=166)
Val/Val	1 (ref.)		1 (ref.)
Val/Ala	0.96 (0.54–1.74)	0.907	1.11 (0.56–2.19)	0.760
Ala/Ala	1.76 (0.93–3.32)	0.080	1.64 (0.83–3.26)	0.157
Val/Ala & Ala/Ala	1.17 (0.68–2.04)	0.563	1.24 (0.67–2.29)	0.487
	Ptrend	0.060
Val/Val & Val/Ala	1 (ref.)		1 (ref.)
Ala/Ala	1.84 (1.13–2.87)	0.014	1.76 (1.03–2.99)	0.035
ER positive	(n=359)		(n=299)
Val/Val	1 (ref.)		1 (ref.)
Val/Ala	1.54 (0.93–2.552)	0.095	1.45 (0.83–2.54)	0.192
Ala/Ala	2.14 (1.24–3.70)	0.007	2.54 (1.35–4.78)	0.004
Val/Ala & Ala/Ala	1.73 (1.07–2.79)	0.024	1.76 (1.04–2.99)	0.035
	Ptrend	0.005
Val/Val & Val/Ala	1 (ref.)		1 (ref.)
Ala/Ala	1.60 (1.07–2.42)	0.024	2.06 (1.32–3.21)	0.001
P53 Mutation negative	(n=424)		(n=340)
Val/Val	1 (ref.)		1 (ref.)
Val/Ala	1.38 (0.87–2.20)	0.171	1.64 (0.98–2.73)	0.060
Ala/Ala	1.98 (1.20–3.26)	0.007	2.58 (1.49–4.45)	0.001
Val/Ala & Ala/Ala	1.58 (1.02–2.44)	0.039	1.90 (1.18–3.53)	0.008
	Ptrend	0.007
Val/Val & Val/Ala	1 (ref.)		1 (ref.)
Ala/Ala	1.60 (1.09–2.35)	0.017	1.89 (1.25–2.85)	0.002
P53 Mutation positive	(n=144)		(n=125)
Val/Val	1 (ref.)		1 (ref.)
Val/Ala	0.82 (0.42–1.58)	0.547	0.76 (0.36–1.56)	0.458
Ala/Ala	1.97 (0.95–4.08)	0.069	1.38 (0.58–3.26)	0.468
Val/Ala & Ala/Ala	1.03 (0.55–1.93)	0.915	0.89 (0.45–1.76)	0.734
	Ptrend	0.038
Val/Val & Val/Ala	1 (ref.)		1 (ref.)
Ala/Ala	2.40 (1.40–4.12)	0.001	1.81 (0.99–3.33)	0.054

^*Cox Proportional-Hazards regression with adjustments for age at diagnosis, study site, race, tumor size, tumor grade, nodal involvement, estrogen receptor status and p53 mutation